Inflammatory Bowel Diseases Increase Risk of Type 2 Diabetes in a Nationwide Cohort Study
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND & AIMS The intestine regulates glucose homeostasis, but it is not clear whether chronic intestinal inflammation affects risk for type 2 diabetes. We investigated the long-term risk of type 2 diabetes in patients with inflammatory bowel diseases (IBD) in a nationwide cohort study in Denmark. METHODS In a nationwide population-based cohort of 6,028,844 persons in Denmark, we compared data from individuals with a diagnosis of IBD (Crohn's disease [CD] or ulcerative colitis UC]) with data from individuals without IBD, from 1977 through 2014. Persons with type 2 diabetes were identified in the National Patient Register. Risk is presented as standardized incidence ratios (SIR) with 95% CIs. RESULTS During 736,072 person-years of follow-up, 3436 patients with IBD developed type 2 diabetes vs 2224 expected (SIR, 1.54; 95% CI, 1.49-1.60). The risk was significantly increased in patients with UC (SIR, 1.54; 95% CI, 1.48-1.60), in patients with CD (SIR, 1.57; 95% CI, 1.47-1.67), in women (SIR, 1.51; 95% CI, 1.44-1.59), and in men (SIR, 1.57; 95% CI, 1.50-1.65). The risk was highest the first year after a diagnosis of IBD (SIR, 4.48; 95% CI, 4.16-4.83), but remained increased for 20 or more years following the diagnosis (SIR, 1.26; 95% CI, 1.16-1.38). The increased risk could not be accounted for by frequency of health care contacts or corticosteroid exposure. Patients who received a diagnosis of IBD from 2003 through 2014 (SIR, 1.79; 95% CI, 1.67-1.91) had a significantly higher risk of type 2 diabetes than patients who received a diagnosis of IBD from 1977 through 1988 (SIR, 1.47; 95% CI, 1.39-1.56) or 1989 through 2002 (SIR, 1.48; 95% CI, 1.41-1.56) (P<.001). CONCLUSIONS In a population-based cohort study, we found an increased risk of type 2 diabetes in patients with UC or CD, with highest risk estimates from 2003 through 2014, compared with earlier years. Studies are needed to determine the effects of IBD treatment on risk of type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Danish National Patient Register
Lynge, E., Sandegaard, J. L., & Rebolj, M. (2011) · Scandinavian Journal of Public Health · doi:10.1177/1403494811401482 · Cited by 3,968
Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota
MetaHIT consortium, Forslund, K., Hildebrand, F., Nielsen, T., Falony, G., Le Chatelier, E., Sunagawa, S., Prifti, E., Vieira-Silva, S., Gudmundsdottir, V., et al. (2015) · Nature · doi:10.1038/nature15766 · Cited by 2,116
Dysbiosis of the faecal microbiota in patients with Crohn’s disease and their unaffected relatives
Joossens, M., Huys, G., Cnockaert, M., De Preter, V., Verbeke, K., Rutgeerts, P., Vandamme, P., & Vermeire, S. (2011) · Gut · doi:10.1136/gut.2010.223263 · Cited by 1,063
New IBD genetics: common pathways with other diseases
Lees, C. W., Barrett, J. C., Parkes, M., & Satsangi, J. (2011) · Gut · doi:10.1136/gut.2009.199679 · Cited by 635
Dregan, A., Charlton, J., Chowienczyk, P., & Gulliford, M. C. (2014) · Circulation · doi:10.1161/circulationaha.114.009990 · Cited by 303
Impaired regulation of the incretin effect in patients with type 2 diabetes
Bagger, J. I., Knop, F. K., Lund, A., Vestergaard, H., Holst, J. J., & Vilsbøll, T. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2435 · Cited by 219
Tam, L.-S., Tomlinson, B., Chu, T. T., Li, T. K., & Li, E. K. (2007) · Clinical Rheumatology · doi:10.1007/s10067-007-0539-8 · Cited by 197
GLP-1 Induces Barrier Protective Expression in Brunnerʼs Glands and Regulates Colonic Inflammation
Bang-Berthelsen, C. H., Holm, T. L., Pyke, C., Simonsen, L., Søkilde, R., Pociot, F., Heller, R. S., Folkersen, L., Kvist, P. H., Jackerott, M., et al. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000847 · Cited by 111
GLP-1 nanomedicine alleviates gut inflammation
Anbazhagan, A. N., Thaqi, M., Priyamvada, S., Jayawardena, D., Kumar, A., Gujral, T., Chatterjee, I., Mugarza, E., Saksena, S., Onyuksel, H., et al. (2017) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2016.08.004 · Cited by 80
Cited by
Zhang, Z., Tanaka, I., Pan, Z., Ernst, P. B., Kiyono, H., & Kurashima, Y. (2022) · European Journal of Immunology · doi:10.1002/eji.202149532 · Cited by 69
Gorelik, Y., Ghersin, I., Lujan, R., Shlon, D., Loewenberg Weisband, Y., Ben-Tov, A., Matz, E., Zacay, G., Dotan, I., Turner, D., et al. (2025) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjae160 · Cited by 41
Ghoneim, S., Shah, A., Dhorepatil, A., Butt, M. U., & Waghray, N. (2020) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s250182 · Cited by 16
“60).(19) In our study, the diagnosis of diabetes was Table 2 Multivariate Regression Analysis”
BackgroundResult
Metadata
- Authors
- Jess, T., Jensen, B. W., Andersson, M., Villumsen, M., & Allin, K. H.
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 18
- Issue
- 4
- Pages
- 881-888.e1
- ISSN
- 1542-3565 (ISSN-L)
- OpenAlex
- W2966680138
- Cited by
- 112
- References
- 9
- FWCI
- 4.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inflammatory Bowel Diseases Increase Risk of Type 2 Diabetes in a Nationwide Cohort Study. https://app.cochat.ai/papers/10.1016/j.cgh.2019.07.052
- The paper
- Jess, T., Jensen, B. W., Andersson, M., Villumsen, M., & Allin, K. H. (2020). Inflammatory Bowel Diseases Increase Risk of Type 2 Diabetes in a Nationwide Cohort Study. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2019.07.052
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.